News Image

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Provided By PR Newswire

Last update: Sep 22, 2023

SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, "Scilex") of certain securities that Sorrento held in Scilex.

Read more at prnewswire.com

SCILEX HOLDING CO

NASDAQ:SCLX (3/3/2025, 8:00:02 PM)

After market: 0.3 +0.01 (+2.95%)

0.2914

+0.06 (+23.47%)


ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (3/3/2025, 8:00:02 PM)

After market: 2.01 +0.01 (+0.5%)

2

-0.09 (-4.31%)



Find more stocks in the Stock Screener

Follow ChartMill for more